#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14172	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2071	680.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1716	1716	T	820	T,C	744,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14172	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2071	680.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1450	1450	C	815	C	757	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14172	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2071	680.2	0	HET	.	.	.	A800G	.	800	800	A	1066	1066	A	847	A,G	595,192	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26242	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3535	740.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1663	1663	A	938	A	880	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26242	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3535	740.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2297	2297	C	776	C	715	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26242	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3535	740.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2371	2371	A	822	A	767	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26242	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3535	740.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2923	2923	C	849	C,T	786,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2154	folP	855	855	100.0	folP.l15.c4.ctg.1	1482	144.2	1	SNP	p	R229S	1	.	.	685	687	AGC	997	999	AGC	236;236;238	A;G;C	221;219;219	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5484	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3412	160.3	1	SNP	p	S91F	1	.	.	271	273	TTC	600	602	TTC	199;199;198	T;T;C	189;190;187	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5484	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3412	160.3	1	SNP	p	D95G	1	.	.	283	285	GGC	612	614	GGC	199;196;197	G;G;C	187;184;184	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5484	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3412	160.3	1	SNP	p	G95N	0	.	.	283	285	GGC	612	614	GGC	199;196;197	G;G;C	187;184;184	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1618	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1384	116.7	1	SNP	p	G45D	0	.	.	133	135	GGC	519	521	GGC	212;213;213	G;G,A,T;C,T	193;192,1,1;192,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	868	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	871	99.0	0	.	n	.	0	A197.	DEL	197	197	A	475	475	A	204	A	195	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5152	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3063	167.7	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1581	1583	GTC	225;227;229	G;T;C	210;212;214	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5152	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3063	167.7	1	SNP	p	D86N	0	.	.	256	258	GAC	687	689	GAC	208;205;203	G,T;A;C	195,1;185;193	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5152	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3063	167.7	1	SNP	p	S87R	1	.	.	259	261	CGT	690	692	CGT	201;199;200	C;G;T	191;186;183	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5152	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3063	167.7	1	SNP	p	R87I	0	.	.	259	261	CGT	690	692	CGT	201;199;200	C;G;T	191;186;183	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5152	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3063	167.7	1	SNP	p	R87W	0	.	.	259	261	CGT	690	692	CGT	201;199;200	C;G;T	191;186;183	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5152	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3063	167.7	1	SNP	p	S88P	0	.	.	262	264	TCC	693	695	TCC	201;204;202	T;C;C	184;188;189	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4464	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2598	170.9	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1286	1288	TGC	246;245;246	T;G;C	220;219;223	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4464	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2598	170.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1496	1498	GGC	222;221;217	G;G;C	202;202;197	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1245	1247	GCA	212;213;216	G;C;A	196;197;204	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1248	1250	ATC	215;216;216	A;T;C	200;201;202	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1260	1262	GTG	221;220;218	G;T,G;G	208;204,1;202	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1260	1262	GTG	221;220;218	G;T,G;G	208;204,1;202	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1764	1766	ACC	170;169;169	A;C;C	155;156;156	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1818	1820	GCG	168;165;165	G;C;G	156;134;141	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1818	1820	GCG	168;165;165	G;C;G	156;134;141	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1941	1943	GGC	199;200;200	G;G;C	182;184;186	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1950	1952	GGC	197;196;193	G,A;G;C	178,1;177;172	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3904	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2430	160.1	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1968	1970	TCG	186;186;186	T,G;C;G	129,6;146;150	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5566	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3046	182.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1583	1585	CCG	209;209;208	C;C;G	185;192;183	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2320	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1843	125.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	585	585	C	162	C	150	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2702	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1480	181.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	402	404	GAA	201;197;198	G;A;A	187;183;182	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2702	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1480	181.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	690	692	GAT	219;218;217	G;A;T	201;199;200	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2702	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1480	181.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	813	815	TCA	239;238;239	T;C;A	217;215;217	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2702	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1480	181.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	942	944	GTC	241;243;241	G,A;T;C,T	223,1;228;227,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2702	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1480	181.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1272	1274	GCA	221;219;218	G;C;A	206;203;201	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2702	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1480	181.0	1	SNP	p	G120K	1	.	.	358	360	AAG	648	650	AAG	227;221;222	A;A;G	214;209;210	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2702	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1480	181.0	1	SNP	p	A121D	1	.	.	361	363	GAC	651	653	GAC	222;221;224	G;A;C	210;207;213	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2702	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1480	181.0	1	SNP	p	D121N	0	.	.	361	363	GAC	651	653	GAC	222;221;224	G;A;C	210;207;213	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	304	porB3	990	116	92.24	porB3.l15.c30.ctg.2	241	35.8	0	.	p	.	0	M18T	NONSYN	52	54	ATG	127	129	ACG	55;54;52	A;C;G	49;49;48	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	304	porB3	990	116	92.24	porB3.l15.c30.ctg.2	241	35.8	0	.	p	.	0	T29A	NONSYN	85	87	ACC	160	162	GCC	43;42;40	G;C;C	39;37;36	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	304	porB3	990	116	92.24	porB3.l15.c30.ctg.2	241	35.8	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	169	171	CAA	30;29;25	C;A;A	28;27;23	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	304	porB3	990	116	92.24	porB3.l15.c30.ctg.2	241	35.8	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	175	177	TAC	12;10;10	T;A;C	12;9;10	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9950	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4777	207.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1913	1915	AAT	235;232;231	A,G;A;T	215,1;214;211	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1026	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1037	98.3	1	SNP	p	V57M	1	.	.	169	171	ATG	495	497	ATG	197;195;192	A;T;G	184;182;177	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
